BOUCHE, Gauthier, Nicolas ANDRÉ, Shripad BANAVALI, Frank BERTHOLD, Alfredo BERRUTI, Guido BOCCI, Giovanni BRANDI, Ugo CAVALLARO, Saviero CINIERI, Marco COLLEONI, Giuseppe CURIGLIANO, Teresa Di DESIDERO, Alexandru ENIU, Nicola FAZIO, Robert KERBEL, Lisa HUTCHINSON, Urszula LEDZEWICZ, Elisabetta MUNZONE, Eddy PASQUIER, Graciela O. SCHAROVSKY, Yuval SHAKED, Jaroslav ŠTĚRBA, Martin VILLALBA a Francesco BERTOLINI. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience. Briston: Cancer Intelligence, 2014, roč. 8, č. 463, s. 1-18. ISSN 1754-6605. Dostupné z: https://dx.doi.org/10.3332/ecancer.2014.463.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan
Autoři BOUCHE, Gauthier (56 Belgie), Nicolas ANDRÉ (250 Francie), Shripad BANAVALI (356 Indie), Frank BERTHOLD (276 Německo), Alfredo BERRUTI (380 Itálie), Guido BOCCI (380 Itálie), Giovanni BRANDI (380 Itálie), Ugo CAVALLARO (380 Itálie), Saviero CINIERI (380 Itálie), Marco COLLEONI (380 Itálie), Giuseppe CURIGLIANO (380 Itálie), Teresa Di DESIDERO (380 Itálie), Alexandru ENIU (642 Rumunsko), Nicola FAZIO (380 Itálie), Robert KERBEL (124 Kanada), Lisa HUTCHINSON (826 Velká Británie a Severní Irsko), Urszula LEDZEWICZ (840 Spojené státy), Elisabetta MUNZONE (380 Itálie), Eddy PASQUIER (250 Francie), Graciela O. SCHAROVSKY (32 Argentina), Yuval SHAKED (376 Izrael), Jaroslav ŠTĚRBA (203 Česká republika, garant, domácí), Martin VILLALBA (250 Francie) a Francesco BERTOLINI (380 Itálie).
Vydání Ecancermedicalscience, Briston, Cancer Intelligence, 2014, 1754-6605.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
Kód RIV RIV/00216224:14110/14:00076839
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3332/ecancer.2014.463
UT WoS 000215844400088
Klíčová slova anglicky Adult; Anti-angiogenesis; Cancer; Child; Drug repurposing; Metronomic chemotherapy; Pharmacoeconomics
Štítky EL OK
Příznaky Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 14. 10. 2014 17:36.
Anotace
The Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24-25 June 2014. The meeting was a true translational meeting where researchers and clinicians shared their results, experiences, and insights in order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, and optimal dosage are still not well understood and that the field would learn a lot from ancillary studies performed during the clinical trials of metronomic chemotherapies. From the pre-clinical side, new research findings indicate additional possible mechanisms of actions of metronomic schedule on the immune and blood vessel compartments of the tumour micro-environment. New clinical results of metronomic chemotherapy were presented in particular in paediatric cancers [especially neuroblastoma and central nervous system (CNS) tumours], in angiosarcoma (together with beta-blockers), in hepatocellular carcinoma, in prostate cancer, and in breast cancer. The use of repurposed drugs such as metformin, celecoxib, or valproic acid in the metronomic regimen was reported and highlighted the potential of other candidate drugs to be repurposed. The clinical experiences from low- and middle-income countries with affordable regimens gave very encouraging results which will allow more patients to be effectively treated in economies where new drugs are not accessible. Looking at the impact of metronomic approaches that have been shown to be effective, it was admitted that those approaches were rarely used in clinical practice, in part because of the absence of commercial interest for companies. However, performing well-designed clinical trials of metronomic and repurposing approaches demonstrating substantial improvement, especially in populations with the greatest unmet needs, may be an easier solution than addressing the financial issue. Metronomics should always be seen as a chance to come up with new innovative affordable approaches and not as a cheap rescue strategy.
VytisknoutZobrazeno: 29. 7. 2024 07:14